Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
20.32
+0.58 (2.94%)
At close: Dec 5, 2025, 4:00 PM EST
20.90
+0.58 (2.85%)
After-hours: Dec 5, 2025, 7:09 PM EST
Syndax Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Syndax Pharmaceuticals stock have an average target of 36.92, with a low estimate of 17 and a high estimate of 56. The average target predicts an increase of 81.69% from the current stock price of 20.32.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Syndax Pharmaceuticals stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 9 | 8 | 9 | 8 |
| Buy | 2 | 2 | 2 | 1 | 1 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 12 | 10 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $22 → $35 | Buy | Maintains | $22 → $35 | +72.24% | Nov 24, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $40 → $33 | Buy | Maintains | $40 → $33 | +62.40% | Nov 12, 2025 |
| UBS | UBS | Strong Buy Maintains $35 → $38 | Strong Buy | Maintains | $35 → $38 | +87.01% | Nov 4, 2025 |
| Barclays | Barclays | Buy Maintains $19 → $22 | Buy | Maintains | $19 → $22 | +8.27% | Nov 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +96.85% | Oct 27, 2025 |
Financial Forecast
Revenue This Year
170.53M
from 23.68M
Increased by 620.14%
Revenue Next Year
367.36M
from 170.53M
Increased by 115.42%
EPS This Year
-3.18
from -3.72
EPS Next Year
-1.73
from -3.18
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 189.5M | 475.6M | ||||
| Avg | 170.5M | 367.4M | ||||
| Low | 155.9M | 231.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 700.4% | 178.9% | ||||
| Avg | 620.1% | 115.4% | ||||
| Low | 558.4% | 35.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.78 | -0.55 | ||||
| Avg | -3.18 | -1.73 | ||||
| Low | -3.35 | -2.95 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.